This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Defining key tasks and accelerating the construction of new urbanization
R&D of Anti-COVID-19 Drugs is Blooming in China
Anti-epidemic stocks moved higher in early trading of the Hong Kong Stock Exchange today, with Kintor Pharma-B (Chinese: 开拓药业,09939:HK) and Shandong Xinhua Pharmaceutical (Chinese: 新华制药,00719:HK) leading the rally on the back of thriving R&D of anti-coronavirus drugs.
Updated 1 hour ago
Co-Working Space Provider Ucommune Experienced Jaw-Dropping Losses
Founded in 2015, the Beijing-based Ucommune (优客工场) is a co-working space provider that creates a large-scale intelligent agile office ecosystem in China. Recently, the company released its second annual report, with net loss reaching CNY 2.163 billion.
Updated 15 hours ago
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
May 12, 2022 05:41 PM